PET/CT with 18-fluor-fluorodeoxyglucose in the follow-up of the cutaneous malignant melanoma
DOI:
https://doi.org/10.25758/may.1164Keywords:
Positron emission tomography, Computed tomography, 18Fluor-fluorodeoxyglucose, Cutaneous malignant melanoma, Follow-upAbstract
Background – Cutaneous malignant melanoma (CMM) is one of the most lethal malignancies and the follow-up involves, in addition to clinical examination and analysis of tumor markers, several imaging methods such as the Positron Emission Tomography/Computed Tomography (PET/CT) exam with 18fluor-fluorodeoxyglucose (18F-FDG). The aim of the study is to evaluate the utility of PET/CT in the assessment of the extension of the disease and of suspected recurrence in the CMM, comparing the imaging findings with those described in CT studies. Methods – It was performed a retrospective analysis of 62 PET/CT studies in 50 patients diagnosed with CMM. It excluded a study that had a doubtful outcome (pulmonary nodule) and it was not possible to perform its diagnosis. The information related to the results of pathologic studies and imaging studies was obtained through medical history and medical reports of CT and PET/CT. A database was created with the collected data through Excel software and a descriptive statistical analysis was carried out. Results – Of the PET/CT studies analyzed, 31 were considered true positives (TP), 28 true negatives (TN), 1 false negative (FN), and 1 false positive (FP). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET/CT for staging and evaluation of suspicious relapse in CMM are, respectively, 96.9%, 96.6%, 96.9%, 96.6%, and 96.7%. From the CT results considered in statistical analysis, 14 corresponded to TP, 12 to TN, 3 to FP, and 5 to FN. The sensitivity, specificity, PPV and NPV, and accuracy of CT for staging and evaluation of suspicious relapse in CMM are, respectively, 73.7%, 80.0%, 82.4%, 70.6%, and 76.5%. Compared to the CT results, PET/CT allowed a change in therapeutic approach in 23% of studies. Conclusion – PET/CT is a useful tool in evaluating CMM, characterized by high diagnostic accuracy in staging and in the evaluation of suspected recurrence of MMC compared to CT only.
Downloads
References
Meiriño R, Martínez E, Marcos M, Villafranca E, Domínguez MA, Illarramendi JJ, et al. Factores pronósticos en el melanoma maligno cutáneo [Prognostic factors in cutaneous malignant melanoma]. Anales Sis San Navarra. 2001;24 Suppl 1:167-72. Spanish
Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008;249(3):836-44.
Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med. 2006;47(6):957-67.
Pinilla I, Rodríguez-Vigil B, Gómez-León N. Integrated 18FDG PET/CT: utility and applications in clinical oncology. Clin Med Oncol. 2008;2:181-98.
Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34(9):1420-7.
Nicol I, Chuto G, Gaudy-Marqueste C, Brenot-Rossi I, Grob JJ, Richard MA. Place de la TEP-TDM au FDG dans le mélanome cutané [Role of FDG PET-CT in cutaneous melanoma]. Bull Cancer. 2008;95(11):1089-101. French
Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6:vi14-21.
Mervic L. Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerol Alp Pannonica Adriat. 2012;21(2):27-31.
Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244(2):566-74.
Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med. 2004;45(8):1323-7.
Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41(9):1491-4.
Xing Y, Cromwell KD, Cormier JN. Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract. 2012;2012:941921.
Mirk P, Treglia G, Salsano M, Basile P, Giordano A, Bonomo L. Comparison between F-Fluorodeoxyglucose positron emission tomography and sentinel lymph node biopsy for regional lymph nodal staging in patients with melanoma: a review of the literature. Radiol Res Pract. 2011;2011:912504.
Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
Heathcote A, Wareing A, Meadows A. CT instrumentation and principles of CT protocol optimization. In Hogg P, Testanera G, editors. Principles and practice of PET/CT – Part 1: a technologist’s guide. European Association of Nuclear Medicine; 2010. p. 54-68. ISBN 9783902785008
Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104(3):570-9.
Yancovitz M, Finelt N, Warycha MA, Christos PJ, Mazumdar M, Shapiro RL, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110(5):1107-14.
Pinheiro AMC, Friedman H, Cabral ALSV, Rodrigues, HA. Melanoma cutâneo: características clínicas, epidemiológicas e histopatológicas no Hospital Universitário de Brasília entre janeiro de 1994 e abril de 1999 [Cutaneous melanoma: clinical, epidemiological and histopathological characteristics at the University Hospital of Brasília between January 1994 and April 1999]. An Bras Dermatol. 2003;78(2):179-86. Portuguese
Gon AS, Minelli L, Guembarovski AL. Melanoma cutâneo primário em Londrina [Primary cutaneous melanoma in Londrina]. An Bras Dermatol. 2001;76(4):413-26. Portuguese
Bower J. Utilization of PET/CT in melanoma. In ISRRT World Congress and CAMRT Annual General Conference, Toronto (Canada), June 7-10, 2012.
Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24(7):1178-87.
Mottaghy FM, Sunderkötter C, Schubert R, Wohlfart P, Blumstein NM, Neumaier B, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging. 2007;34(9):1355-64.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Saúde e Tecnologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.
The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).
All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.
